NASDAQ : NEUP

Neuphoria Therapeutics Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 3.05 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 16.50M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.

Details

NameNeuphoria Therapeutics Inc.
SectorHealthcare
IndustryBiotechnology
Employees1
Founded1996
CeoSpyridon Papapetropoulos
CountryUnited States
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyUSD
IsinUS64136E1029
Cusip64136E102
Cik0001191070
Sic2834

Key executives

NameTitle
Dr. Spyridon Papapetropoulos M.D., Ph.D.Interim Chief Executive Officer and Executive Director
Timothy M. Cunningham CPA, M.B.A.Fractional Chief Financial Officer
Dr. Julie Kerner Ph.D.Senior Vice President of Business Operations
Adrian Hinton BEC, F.C.A.Financial Controller
Rajeev Chandra B.Com., C.A., M.B.A.Company Secretary

Contact

Address14 Milliston Road, Box 195, Millis, Massachusetts 02054, United States
Phone339 240 6066
Websitehttps://www.neuphoriatx.com